Close Menu

circulating tumor DNA

The team plans to integrate the method, which combines mutation enrichment with duplex sequencing, into its platform to detect minimal residual disease in blood.

Despite challenges related to the coronavirus pandemic, the Chinese precision oncology firm reported total quarterly revenues of RMB131.7 million ($20.2 million).

The firm will build liquid biopsy companion diagnostic tests that complement its tissue-based assays and are tailored for drugs developed by pharma partners.

The companies will partner on applications including oncology diagnostics, cell-free and circulating tumor DNA assays, and single-cell genomics.

The company is working to expand access to its liquid biopsy assay outside of the US, after receiving US Food and Drug Administration approval last year.

The company recently announced a deal with personalized ctDNA testing firm Natera and will now follow that with the launch of its own MRD product this year.

The company doesn’t expect significant revenue from the test this year, but executives said that they are already seeing positive reception trends.

The firm expects to release an expanded liquid biopsy panel this year to help pharmaceutical partners perform blood-based biomarker discovery work. 

The firm said its revenues for the three months ended Dec. 31, 2020 were $78.3 million compared to $62.9 million in the same quarter of 2019.

The Chinese company will use the funds to accelerate the registration and commercialization of its NGS-based products for cancer screening and early detection.

Pages

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.